Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with cardiovascular disease. The company has three programs in the mid to late stages of clinical development that are based on its autologous CD34+ cell therapy platform to treat coronary microvascular dysfunction, critical limb ischemia and no-option refractory disabling angina.